Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …

Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Background Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver
disease associated with liver-related complications and death. The efficacy and safety of …

Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …

Importance Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021,
the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Nonalcoholic fatty liver disease (NAFLD) is a dynamic chronic liver disease that develops in
close association with metabolic irregularities. Between 2016 and 2019, the global …

Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the
leading causes of chronic liver disease worldwide. NAFLD and ALD share …